Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Summary

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis. The aim of this study is to evaluate the safety and efficacy of ADSTEM Inj. against Placebo in the treatment of atopic dermatitis in patients with moderate to severe acute and chronic atopic.

Timeline

Start

2019-12-11

Primary completion

2023-01-26

Completion

2027-10-31

Publications

• Seok J, Kim SY, Lee WG, Shin MK, Lee DH, Seo YJ, Cho S, Park KY, Son SW, Lee SH, Seo JS, Seo SJ. Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial. Stem Cell Res Ther. 2025 Dec 2;16(1):671. doi: 10.1186/s13287-025-04763-y.

Drugs

Indications